drugset / Trial / NCT01495793

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

NCT01495793

Phase 2 Completed 42 enrolled UCB BIOSCIENCES, Inc.
NaSingle-groupOpen-labelOther

Summary

This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple administrations of the rotigotine transdermal system. The study was conducted in adolescent subjects (13 to \<18 years of age) with idiopathic Restless Legs Syndrome (RLS).

Timeline

Start
2011-12
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 3 mg Other